8.2 Immune-Mediated Hemolytic Anemia (IMHA) & Immune-Mediated Thrombocytopenia (IMTP)

Immune-Mediated Hemolytic Anemia (IMHA) & Immune-Mediated Thrombocytopenia (IMTP)

Immune-mediated hematologic disorders represent some of the most challenging and high-mortality emergencies encountered in small animal critical care. Immune-Mediated Hemolytic Anemia (IMHA) and Immune-Mediated Thrombocytopenia (IMTP) arise from a breakdown in self-tolerance, leading to humoral autoantibody production and rapid cytotoxic destruction of red blood cells and platelets, respectively. Concurrent presentation of both conditions is recognized as Evans Syndrome.

1. Pathophysiology of IMHA: Extravascular vs. Intravascular Hemolysis

IMHA is fundamentally a Type II hypersensitivity reaction. Host autoantibodies (primarily IgG, and less commonly IgM) bind directly to surface antigens (such as glycophorins and Band 3 membrane transport proteins) on circulating red blood cells.

[Mechanisms of Immune-Mediated Erythrocyte Destruction]
                      Autoantibody Binding (IgG / IgM)
                                     │
            ┌────────────────────────┴────────────────────────┐
            ▼                                                 ▼
  [EXTRAVASCULAR HEMOLYSIS]                         [INTRAVASCULAR HEMOLYSIS]
  • IgG-coated RBCs recognized by                   • IgM (or high IgG) activates full
    Fc-receptors on macrophages                       Complement Cascade (C1-C9)
  • Partial phagocytosis in spleen/liver            • Formation of Membrane Attack Complex (MAC)
  • Loss of membrane -> Spherocyte Formation        • Direct osmotic lysis in circulation
  • Bilirubinemia / Bilirubinuria                   • Hemoglobinemia / Hemoglobinuria
  • Splenomegaly / Hepatomegaly                     • Severe Acute Kidney Injury (Pigment Nephropathy)

Extravascular Hemolysis (The Predominant Pathway)

• Mechanism: IgG-coated erythrocytes pass through the splenic and hepatic sinusoids, where Fc and C3b receptors on tissue macrophages bind to the antibody-coated red cell membrane.
• Spherocyte Generation: Macrophages engulf portions of the red cell membrane without ingesting the entire cell. The remaining membrane seals around the intracellular hemoglobin, creating a spherical cell with reduced surface-area-to-volume ratio: the spherocyte. Spherocytes are rigid, unyielding, and rapidly trapped and destroyed during subsequent passages through the reticuloendothelial system.
• Laboratory Hallmarks: Hyperbilirubinemia, bilirubinuria, icterus, and splenomegaly. Free hemoglobin is not released into plasma.

Intravascular Hemolysis (The High-Mortality Pathway)

• Mechanism: Large pentameric IgM autoantibodies (or dense IgG clusters) bind red cells and fix complement through the classical pathway, driving the formation of the Membrane Attack Complex (C5b-C9 MAC). MAC bores large pores into the erythrocyte membrane, causing immediate intravascular osmotic lysis.
• Laboratory Hallmarks: Gross hemoglobinemia (pink/red plasma after centrifugation) and hemoglobinuria (port-wine colored urine that does not clear with centrifugation). Free hemoglobin binds haptoglobin; once saturated, free dimeric hemoglobin passes through the renal glomeruli, causing direct renal tubular toxicity, acute tubular necrosis, and acute kidney injury (pigment nephropathy).

2. Diagnostic Hallmarks of IMHA

According to the ACVIM Consensus Statement on the diagnosis of IMHA, definitive diagnosis requires evidence of anemia, evidence of hemolysis, and at least two of the following immunologic hallmarks:

1. Spherocytosis

• Morphology: Spherocytes appear as small, intensely hyperchromic, perfectly spherical erythrocytes that completely lack central pallor.
• Species Significance: Spherocytes are easily recognized and highly specific in dogs, because normal canine erythrocytes have a prominent biconcave disk shape with clear central pallor. In cats, normal erythrocytes naturally lack central pallor; therefore, spherocytes cannot be reliably identified on feline blood smears.

2. Persistent Saline Autoagglutination (Saline Wash Test)

• Purpose: Differentiates true immunologic autoagglutination from rouleaux formation (non-specific erythrocyte stacking associated with hyperglobulinemia/hyperfibrinogenemia).
• Protocol: Place 1 drop of EDTA whole blood on a glass slide and add 4 to 9 drops of 0.9% NaCl (a 1:4 or 1:9 dilution). Gently rock the slide. If gross clumping remains, perform a formal saline wash (centrifuge diluted blood, discard supernatant, resuspend in saline 3 times).
• Interpretation: Rouleaux disperses into a smooth suspension; true autoagglutination persists as distinct macro- or microscopic "grape-like" clusters.

3. Direct Antiglobulin Test (DAT / Coombs' Test)

• Detects host anti-erythrocyte antibodies (IgG, IgM) or complement fragments (C3) bound to patient red cells.
• May yield false negatives if antibody titers are low or if the patient has received prior high-dose corticosteroid therapy; false positives occur in severe inflammatory states.

4. Regenerative vs. Non-Regenerative Patterns

• Regenerative Anemia: Marked reticulocytosis (absolute reticulocyte count >100,000/uL in dogs; aggregate reticulocytes >60,000/uL in cats), polychromasia, anisocytosis, and nucleated RBCs (nRBCs). Note that bone marrow regeneration requires 3 to 5 days to mount.
• Non-Regenerative / Precursor-Targeted Immune-Mediated Anemia (PIMA): When autoantibodies target erythroid progenitor cells (rubriblasts, prorubricytes) within the bone marrow, severe non-regenerative anemia or Pure Red Cell Aplasia (PRCA) ensues.

3. Pulmonary Thromboembolism (PTE) & Thromboprophylaxis Protocols

Canine IMHA is one of the most pro-thrombotic diseases in veterinary medicine, with Pulmonary Thromboembolism (PTE) occurring in 30% to 80% of fatal cases at necropsy.

The Pro-Thrombotic State (Virchow's Triad in IMHA)

1. Endothelial Damage: Systemic cytokine storm (TNF-$\alpha$, IL-6), intravascular hemolysis releasing free toxic heme, and indwelling intravenous catheters disrupt vascular endothelium.
2. Hypercoagulability: Massive expression of Tissue Factor on monocytes, platelet activation by free hemoglobin/microparticles, and accelerated consumption/loss of Antithrombin III (ATIII).
3. Hemodynamic Stasis: Severe anemia-induced peripheral vasodilation and cage rest.

Clinical Presentation of Acute PTE

• Sudden onset of severe respiratory distress, tachypnea, and cyanosis in an IMHA patient.
• The Classic Discrepancy: Severe hypoxemia ($P\text{aO}_2 < 60\text{ mmHg}$, $S\text{pO}_2 < 90%$) that is refractory to supplemental oxygen, accompanied by auscultatorily clear lung fields and normal thoracic radiographs during early stages (the "naked radiograph" with severe dyspnea).

Standard Thromboprophylaxis Protocols

Thromboprophylaxis must be initiated immediately upon diagnosis in all dogs with IMHA (unless severe concurrent thrombocytopenia <30,000/uL is present):

4. Medical Management: Immunosuppression & Transfusion Strategies

Primary Immunosuppressive Therapy

1. Glucocorticoids (First-Line):
   • Mechanism: Rapid down-regulation of macrophage Fc-receptor expression (inhibiting phagocytosis within 24–48 hours), blunting cytokine release, and decreasing antibody production over weeks.
   • Canine Protocol: Prednisone or Prednisolone: $2.0\text{ mg/kg/day PO}$ (or $1.0\text{ mg/kg PO q12h}$; max dose $60\text{ mg/day}$ in large dogs).
   • Parenteral Alternative: Dexamethasone Sodium Phosphate (SP): $0.2\text{–}0.3\text{ mg/kg IV q24h}$ (utilizing a 7:1 to 10:1 potency ratio relative to prednisone).
   • Feline Protocol: Prednisolone: $2.0\text{–}4.0\text{ mg/kg/day PO}$ (cats lack hepatic conversion of prednisone to prednisolone).
2. Second-Line / Adjunctive Immunosuppressive Agents:
   • Indicated if severe autoagglutination, intravascular hemolysis, rapid drop in PCV despite steroids, or to enable faster steroid weaning in large breeds.
   • Cyclosporine (Atopica): $5\text{–}10\text{ mg/kg/day PO}$ (Calcineurin inhibitor; suppresses T-lymphocyte activation and IL-2 transcription).
   • Mycophenolate Mofetil (MMF): $8\text{–}10\text{ mg/kg PO/IV q12h}$ (Inosine monophosphate dehydrogenase inhibitor; blocks purine synthesis in lymphocytes).
   • CRITICAL CONTRAINDICATION: Azathioprine in Cats! Azathioprine ($2.0\text{ mg/kg PO q24–48h}$ in dogs) causes fatal, irreversible bone marrow aplasia and panleukopenia in felines due to deficient thiopurine methyltransferase (TPMT) metabolism.

Transfusion Philosophy in IMHA

• Never withhold blood products from a critically anemic, hypoxemic IMHA patient out of fear of "fueling the fire"! Transfused red blood cells carry vital oxygen to ischemic tissues. Although transfused cells will eventually be cleared by circulating autoantibodies, they provide life-saving hemodynamic and oxygen delivery support while immunosuppressants take effect.
• Always administer DEA 1.1-negative, crossmatch-compatible Packed Red Blood Cells (pRBCs).

5. Immune-Mediated Thrombocytopenia (IMTP / ITP)

Immune-Mediated Thrombocytopenia results from autoantibody-mediated destruction of platelets. Anti-platelet IgG antibodies bind to platelet surface glycoproteins (GPIIb/IIIa), marking them for rapid clearance by splenic and hepatic macrophages.

[Primary vs. Secondary Hemostasis Bleeding Manifestations]
  PRIMARY HEMOSTATIC DEFECT (IMTP)        SECONDARY HEMOSTATIC DEFECT (Coagulopathy)
  • Platelet count <10,000-20,000/uL      • Normal platelets; prolonged PT / aPTT
  • Petechiae (pinpoint hemorrhages)      • Cavitary hemorrhage (hemoabdomen, hemothorax)
  • Ecchymoses (bruising/purpura)         • Hematomas / deep muscle bleeding
  • Mucosal bleeding (epistaxis,          • Hemarthrosis (bleeding into joints)
    melena, gingival bleeding, hematuria)

Clinical Presentation & Diagnostic Criteria

• Profound Thrombocytopenia: Platelet counts typically drop to $<10,000\text{ to }20,000/\mu\text{L}$ (normal reference range: $150,000\text{–}400,000/\mu\text{L}$). Spontaneous hemorrhage is rare when platelets remain $>30,000/\mu\text{L}$.
• Primary Hemostatic Bleeding: Petechiae on the pinnae, gingiva, and inguinal skin; ecchymoses; epistaxis; hematuria; melena; and scleral hemorrhage.

Emergency Management of IMTP

1. Glucocorticoids: Prednisone ($2\text{ mg/kg/day PO}$) or Dexamethasone SP ($0.2\text{–}0.3\text{ mg/kg IV}$).
2. Vincristine (Single Ultra-Low Dose):
   • Dosage: $0.02\text{ mg/kg IV}$ (or $0.5\text{ mg/m}^2 IV$) as a single slow peripheral IV bolus.
   • Mechanism: Vinca alkaloid that binds tubulin, impairing macrophage phagocytic function and stimulating megakaryocyte endomitosis, fragmentation, and premature release of platelets. Accelerates platelet recovery to $>40,000/\mu\text{L}$ within 2 to 3 days (compared to 5–7 days with steroids alone).
3. Human Intravenous Immunoglobulin (hIVIG):
   • Dosage: $0.5\text{–}1.0\text{ g/kg IV}$ administered as a constant rate infusion over 6 to 12 hours.
   • Mechanism: Saturates and blocks macrophage Fc receptors, preventing antibody-coated platelet destruction.
4. Platelet Transfusion Caution: Transfused platelets are destroyed within minutes to hours by circulating autoantibodies. Platelet transfusions (PRP or lyophilized platelets) are strictly reserved for active, life-threatening CNS, pulmonary, or massive gastrointestinal hemorrhage.